BioCryst Pharmaceuticals has received a consensus rating of Buy.
Similarly Will BCRX go up? The 12 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 17.50, with a high estimate of 30.00 and a low estimate of 14.00. The median estimate represents a +53.64% increase from the last price of 11.39.
Is BCRX overvalued? Slightly overvalued with limited growth.
Additionally, What is the target price for BCRX stock?
Stock Price Targets
| High | $30.00 |
|---|---|
| Median | $17.50 |
| Low | $14.00 |
| Average | $19.50 |
| Current Price | $12.59 |
il y a 4 jours
Is BioCryst a good investment?
Is BioCryst Pharmaceuticals stock A Buy? Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for BioCryst Pharmaceuticals stock to perform well in the short-term.
Is BioCryst Pharmaceuticals a good stock to buy? Zacks’ proprietary data indicates that BioCryst Pharmaceuticals, Inc. is currently rated as a Zacks Rank 4 and we are expecting a below average return from the BCRX shares relative to the market in the next few months.
Is BioCryst a good stock to buy? Is BioCryst Pharmaceuticals stock A Buy? The BioCryst Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe BioCryst Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
Is Bcrx undervalued? BioCryst climbs after being named ‘the most undervalued stock in the market’ The influential retail investor crowd has a new favorite: BioCryst Pharmaceuticals (NASDAQ:BCRX). The stock has rallied ~22.3% in the premarket after a post in r/wallstreetbets called it ‘the most undervalued stock in the market.
Why is BioCryst going up?
The big gain came after the company provided an upbeat update on Monday. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. This figure brings the full-year 2021 sales for the drug to $122 million.
Is Bcrx overvalued? Slightly overvalued with limited growth.
When did BCRX go public?
When was BioCryst founded and when did the company go public? BioCryst was founded in 1986 and completed its Initial Public Offering in March 1994. The Company’s stock is traded on the NASDAQ exchange under the symbol BCRX.